Should we measure the bioavailability of interferon β in vivo in patients with multiple sclerosis?

Nature Clinical Practice Neurology

Volumn 5, Issue 3, 2009, Pages 126-127

  Hemmer, Bernhard ^a   Berthele, Achim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; DIAGNOSTIC VALUE; DRUG BIOAVAILABILITY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; IN VIVO STUDY; MULTIPLE SCLEROSIS; NOTE; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 62549156315     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro1042     Document Type: Note

References (6)

1. Hemmer B et al. (2005) Immune response to immunotherapy: The role of neutralising antibodies to interferon β in the treatment of multiple sclerosis. Lancet Neurol 4: 403-412
2. Sørensen PS et al. (2005) Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Eur J Neurol 12: 817-827
3. Goodin DS et al. (2007) Neutralizing antibodies to interferon beta: Assessment of their clinical and radiograpAic impact: an evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68 977-984
4. van der Voort LF et al. (2008) Interferon-β bioactivity measurement in multiple sclerosis: Feasibility for routine clinical practice. Mult Scler [doi:10.1177/1352458508096877]
5. Cunningham S et al. (2005) Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 78 635-646
6. Hoffmann S et al. (2008) HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am J Hum Genet 83 219-227